Nortriptyline

Generic Name: Nortriptyline

Brand Names: Aventyl, Pamelor

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₁N

CAS Number: 72-69-5

Unique Ingredient Identifier: BL03SY4LXB

Background: Nortriptyline hydrochloride, the active metabolite of amitriptyline, is a tricyclic antidepressant (TCA). It is used in the treatment of major depression and is also used off-label for chronic pain and other conditions.

Indication: Nortriptyline is indicated for the relief of the symptoms of major depressive disorder (MDD). Some off-label uses for this drug include treatment of chronic pain, myofascial pain, neuralgia, and irritable bowel syndrome.

Associated Conditions: Chronic Pain, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Myofascial Pain Syndrome, Pain, Orofacial, Postherpetic Neuralgia

Clinical Trials

Management of Acute Tinnitus With Migraine Medications

Phase 4

Recruiting

Conditions: Tinnitus

Interventions: Drug: Nortriptyline
Drug: Paroxetine
Drug: Topiramate
Drug: Verapamil

First Posted Date: 2025-01-29

Last Posted Date: 2025-05-02

Lead Sponsor: University of California, Irvine

Target Recruit Count: 100

Registration Number: NCT06799169

Locations: 🇺🇸
University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States

Treatment of Meniere's Disease With Migraine Medications

Phase 4

Recruiting

Conditions: Ménière

Interventions: Drug: nortriptyline + topiramate

First Posted Date: 2022-10-17

Last Posted Date: 2024-08-09

Lead Sponsor: University of California, Irvine

Target Recruit Count: 100

Registration Number: NCT05582837

Locations: 🇺🇸
University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States

RCT of Brain Longitudinal Biomarker Study (OPT-Neuro RCT)

Phase 4

Completed

Conditions: Depression
Dementia
Mild Cognitive Impairment
Treatment Resistant Depression
Treatment-Refractory Depression
Major Depressive Disorder
Late Life Depression
Geriatric Depression

Interventions: Drug: Aripiprazole Augmentation
Drug: Bupropion Augmentation
Drug: Switch to bupropion
Drug: Lithium Augmentation
Drug: Switch to nortriptyline

First Posted Date: 2022-09-08

Last Posted Date: 2024-11-25

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 87

Registration Number: NCT05531591

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
🇺🇸
Columbia University Adult and Late Life Depression Clinic, New York, New York, United States
🇺🇸
UCLA Late-Life Mood, Stress, and Wellness Research Program, Los Angeles, California, United States

and more 1 locations

Treatment of Tinnitus With Migraine Medications

Phase 4

Recruiting

Conditions: Tinnitus
Tinnitus, Subjective

Interventions: Drug: Verapamil + paroxetine
Other: Placebo
Drug: Nortriptyline + topiramate

First Posted Date: 2020-05-27

Last Posted Date: 2023-01-09

Lead Sponsor: University of California, Irvine

Target Recruit Count: 150

Registration Number: NCT04404439

Locations: 🇺🇸
University of California, Irvine Medical Center ENT Clinic (Pavilion 2), Orange, California, United States

Pediatric Concussion Outcomes

Phase 4

Terminated

Conditions: Headaches Posttraumatic
Concussion Post Syndrome
Mild Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Nortriptyline

First Posted Date: 2020-01-13

Last Posted Date: 2024-05-29

Lead Sponsor: Lancaster General Hospital

Target Recruit Count: 8

Registration Number: NCT04226365

Locations: 🇺🇸
Penn Medicine Lancaster General Health, Lancaster, Pennsylvania, United States

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

Phase 2

Completed

Conditions: Vestibulodynia
Temporomandibular Disorder
Migraines
Tension Headache
Fibromyalgia Syndrome
Interstitial Cystitis
Chronic Fatigue Syndrome
Back Pain
Irritable Bowel Syndrome
Endometriosis

Interventions: Drug: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream
Drug: Nortriptyline
Drug: Placebo pill
Drug: Placebo cream

First Posted Date: 2019-02-18

Last Posted Date: 2024-06-07

Lead Sponsor: Duke University

Target Recruit Count: 223

Registration Number: NCT03844412

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States

Nortriptyline for the Treatment of Functional Dyspepsia

Phase 3

Conditions: Functional Dyspepsia

Interventions: Drug: Placebo
Drug: Nortriptyline

First Posted Date: 2018-08-29

Last Posted Date: 2018-09-05

Lead Sponsor: Maastricht University Medical Center

Target Recruit Count: 154

Registration Number: NCT03652571

Locations: 🇳🇱
Medisch Spectrum Twente, Enschede, Netherlands
🇳🇱
Tergooi Hilversum, Hilversum, Netherlands
🇳🇱
Alrijne ziekenhuis, Leiden, Netherlands

and more 11 locations

Antidepressants Trial in Parkinson's Disease

Phase 3

Completed

Conditions: Depression
Parkinson Disease

Interventions: Drug: Placebo
Drug: Nortriptyline
Drug: Escitalopram

First Posted Date: 2018-08-29

Last Posted Date: 2023-05-06

Lead Sponsor: University College, London

Target Recruit Count: 52

Registration Number: NCT03652870

Locations: 🇬🇧
Royal Free London NHS Foundation Trust, London, United Kingdom

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

Phase 4

Completed

Conditions: Treatment Resistant Depression
Major Depressive Disorder
Treatment-Refractory Depression
Late Life Depression
Geriatric Depression

Interventions: Drug: Aripiprazole Augmentation
Drug: Switch to bupropion
Drug: Lithium Augmentation
Drug: Bupropion Augmentation
Drug: Switch to nortriptyline

First Posted Date: 2016-11-10

Last Posted Date: 2024-10-03

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 742

Registration Number: NCT02960763

Locations: 🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada
🇺🇸
Washington University School of Medicine Healthy Mind Lab, Saint Louis, Missouri, United States
🇺🇸
UCLA Late-Life Mood, Stress, and Wellness Research Program, Los Angeles, California, United States

and more 2 locations

Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Lithium Carbonate
Drug: Sertraline
Drug: Nortriptyline
Drug: Risperidone

First Posted Date: 2016-09-28

Last Posted Date: 2020-11-20

Lead Sponsor: Federal University of Rio Grande do Sul

Target Recruit Count: 78

Registration Number: NCT02918097

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy